相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Chih-Hao Lu et al.
SCIENTIFIC REPORTS (2022)
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres et al.
LEUKEMIA (2021)
Human and mouse PD-L1: similar molecular structure, but different druggability profiles
Katarzyna Magiera-Mularz et al.
ISCIENCE (2021)
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments
Elena Jachetti et al.
CELLULAR IMMUNOLOGY (2021)
Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells
Maria Davern et al.
TRANSLATIONAL ONCOLOGY (2021)
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Kyohei Nakamura et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Neddylation inactivation represses androgen receptor transcription and inhibits growth, survival and invasion of prostate cancer cells
Xiaochen Zhou et al.
NEOPLASIA (2020)
The Negative Cross-Talk between SAG/RBX2/ROC2 and APC/C E3 Ligases in Regulation of Cell Cycle Progression and Drug Resistance
Shizhen Zhang et al.
CELL REPORTS (2020)
The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells
Yuan Yin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Yosi Gilad et al.
SCIENTIFIC REPORTS (2019)
Coffee and pancreatic cancer risk among never-smokers in the UK prospective Million Women Study
Charlie D. Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Protein neddylation and its alterations in human cancers for targeted therapy
Lisha Zhou et al.
CELLULAR SIGNALLING (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
Hua Li et al.
NEOPLASIA (2017)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Jatin J. Shah et al.
CLINICAL CANCER RESEARCH (2016)
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos et al.
CLINICAL CANCER RESEARCH (2016)
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
Panpan Zhang et al.
CANCER SCIENCE (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
Shailender Bhatia et al.
INVESTIGATIONAL NEW DRUGS (2016)
Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo
Xiaochen Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
Hidetoshi Sumimoto et al.
PLOS ONE (2016)
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
Ronan T. Swords et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Erbin is a novel substrate of the Sag-βTrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesis
Chuan-Ming Xie et al.
JOURNAL OF CELL BIOLOGY (2015)
Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy
Yongchao Zhao et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1-PD-L1 Axis
Zhi-Chun Ding et al.
CANCER RESEARCH (2014)
Neddylation plays an important role in the regulation of murine and human dendritic cell function
Nathan Mathewson et al.
BLOOD (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth
Zhongguang Luo et al.
CANCER RESEARCH (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
James E. Brownell et al.
MOLECULAR CELL (2010)
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Teresa A. Soucy et al.
CLINICAL CANCER RESEARCH (2009)
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy et al.
NATURE (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Novel substrates and functions for the ubiquitin-like molecule NEDD8
Dimitris P. Xirodimas
BIOCHEMICAL SOCIETY TRANSACTIONS (2008)
Function and regulation of protein neddylation - 'Protein Modifications: Beyond the Usual Suspects' review series
Gwenael Rabut et al.
EMBO REPORTS (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Extension of the rank sum test for clustered data: Two-group comparisons with group membership defined at the subunit level
Bernard Rosner et al.
BIOMETRICS (2006)
AP-1 subunits: quarrel and harmony among siblings
J Hess et al.
JOURNAL OF CELL SCIENCE (2004)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
